Cocaine-Related Disorders Clinical Trial
Official title:
Tiagabine for the Treatment of Cocaine Dependence in Methadone-Maintained Individuals
Many opioid-dependent individuals are also dependent on cocaine. Methadone is a widely used and effective method for treating opioid dependence. However, it is not effective in treating other drugs of abuse. The purpose of this study is to determine the effectiveness of another drug, tiagabine, for treating cocaine dependence in opioid-dependent individuals already receiving methadone treatment.
For over 30 years, methadone has been used to treat opioid addiction. Since methadone is
effective in reducing withdrawal symptoms, it is used as a method of detoxification for
opiate addicts. However, methadone is not effective in treating other drugs of abuse, such
as cocaine. Tiagabine is a drug that enhances levels of gamma aminobutyric acid (GABA), a
chemical found in the brain and spinal cord. The objective of this study is to determine the
effectiveness of tiagabine in modifying cocaine-using behavior and reducing opiate
withdrawal symptoms among newly admitted methadone-treated patients.
This 16-week, double-blind, placebo-controlled clinical trial will involve 120 participants
who are both cocaine- and opioid- dependent. Participants will be randomly assigned to
receive either tiagabine or placebo, while concurrently receiving methadone treatment.
Baseline cocaine use will be determined during the first two weeks of treatment. The study
will include three overlapping phases. The first phase will include a one-week fixed
methadone induction (Week 1), as well as flexible methadone stabilization (Weeks 2-13).
Phase two will consist of a 12-week treatment period (Weeks 2-13). This will consist of
tiagabine induction and stabilization. Phase three will include a 4-week taper,
detoxification, or transfer period (Weeks 14-17). After completion of treatment, a 3-month
follow-up visit will occur.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01526538 -
Improving Learning-based Treatment of Cocaine Dependence With Medication
|
Phase 2 | |
| Completed |
NCT00877435 -
Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial
|
N/A | |
| Completed |
NCT00430690 -
Acoustic Startle Reduction In Cocaine Dependence
|
||
| Completed |
NCT00217997 -
Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals
|
N/A | |
| Active, not recruiting |
NCT00094315 -
Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1
|
Phase 1 | |
| Terminated |
NCT00142883 -
The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3
|
N/A | |
| Completed |
NCT00218348 -
Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo
|
Phase 2 | |
| Completed |
NCT00158132 -
Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2
|
Phase 2 | |
| Completed |
NCT00142844 -
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
|
Phase 2 | |
| Completed |
NCT00015054 -
Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3
|
Phase 2 | |
| Completed |
NCT00000294 -
Effects of Carvedilol on Cocaine Use in Humans - 11
|
Phase 2 | |
| Completed |
NCT00000308 -
Dextroamphetamine-Cocaine Behavioral Intervention - 5
|
Phase 2 | |
| Completed |
NCT00000278 -
Disulfiram for Cocaine-Alcohol Abuse - 3
|
Phase 2 | |
| Completed |
NCT00000282 -
Pemoline for Cocaine Abuse - 7
|
Phase 2 | |
| Completed |
NCT00000277 -
Mazindol for Cocaine Abuse - 2
|
Phase 2 | |
| Completed |
NCT00000188 -
Selegiline in Treatment of Cocaine Dependence - 2
|
Phase 2 | |
| Completed |
NCT00000281 -
Pharmacotherapy for Schizophrenic Drug Users - 6
|
Phase 2 | |
| Completed |
NCT00000280 -
Glutaminergic Agents for Cocaine Abuse - 5
|
Phase 1 | |
| Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 | |
| Terminated |
NCT00000276 -
Dopamine Reuptake Inhibitors of Cocaine Abuse - 1
|
Phase 1 |